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ABSTRACT 
A simple, rapid, precise and accurate RP-HPLC method was developed and validated for the determination of Bortezomib, in bulk and 
pharmaceutical dosage form. The separation is achieved on RP-HPLC using a PDA detector by incorporation of enpower 2 software with a flow 
rate of 1.0ml/min using a mixture of Methanol and water (15:85% v/v) as mobile phase. The column used was Hypersil C18 (4.6×150mm, 5µ) at 
a wave length of 284nm. The retention time of the Bortezomib was 3.515min.. The linearity of the drug was 25-125µg/m and the method 
precision for the determination of assay was below 2.0% RSD. The proposed method was validated and applied for the estimation of Bortezomib 
in quality control of bulk and pharmaceutical dosage forms. 
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INTRODUCTION 
Bortezomib is the drug used for the treatment of specific 
type of cancer. It is a protease inhibitor for the treatment of 
multiple myloma .The IUPAC name of Bortezomib is [(1R)-3-
methyl-1-({(2S)-3- phenyl2-[(pyrazin-2-ylcarbonyl) amino] 
propanoyl} amino) butyl] boronic acid, Structure of 
Bortezomib shown in Figure 1. Bortezomib is a peptide 
analogue that reversibly inhibits the protein proteasome 
subunit beta type-5 (PSMB5), which is part of the 
20Sproteasome complex. Its empirical formula is 
C19H25BN4O4 .It is a white powder consists of molecular 
weight 361.03 and soluble in polar solvents like water, 
methanol etc. On November 20, 2015, the U.S. Food and Drug 
Administration approved Bortezomib for the treatment of 
multiple myeloma. 
Bortezomib is not official in any Pharmacopoeia. A literature 
survey on Bortezomib revealed that, until now no analytical 
method was reported for its determination in bulk drug and 
its capsule dosage form. 
 
Figure 1: Bortezomib 1 
Since literature did not cite any method for determination of 
this drug from bulk drug as well as its formulation it was 
proposed to develop and validate a new method by using RP-
HPLC method2. 
MATERIALS AND METHODS  
The method development and validation was done by using 
waters Alliance 2895 seperation model with a PDA detector 
996model.the data was acquired using Enpower 2 software 
and the column used was Hypersil C18, 150 x4.6mm, 5 µ. 
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Bortezomib is not official in any Pharmacopoeia. A literature 
survey on Bortezomib revealed that, until now no analytical 
method was reported for its determination in bulk drug and 
its capsule dosage form. Since literature did not cite any 
method for determination of this drug from bulk drug as well 
as its formulation it was proposed to develop and validate a 
method by using RP-HPLC method2. 
Instrumentation and analytical conditions: 
The method development and validation was done by using 
Waters Alliance 2895 seperation model with a PDA detector 
996model.The data was acquired using Enpower 2 software 
and the column used was Hypersil C18, 150 x4.6mm, 5µ. 
Labman Digital Ultra sonicator was used for enhancing 
dissolution of the drug. A Lab india make pH meter was used 
for pH adjustment. 
Chemicals and Reagents: 
Pure Bortezomib gift sample was obtained from Sura 
Pharma Reaseach Lab, Hyderbaded. HPLC grade water, 
Methanol-HPLC,Acetonitrile-HPLC from Merck ,Mumbai.. 
Labman Digital Ultra sonicator was used for enhancing 
dissolution of the drug. A Lab india make pH meter was used 
for pH adjustment. 
Preparation of Mobile phase, Standard and Sample 
preparations: 
Preparation of Mobile phase: 
Accurately measure 150 ml (15%) of HPLC Methanol and 
850 ml of HPLC Water (85%) were mixed and degassed with 
a digital ultrasonicater for 10 minutes and then filtered 
through 
0.45 µ filter under vacuum filtration. The Mobile phase was 
used as the diluent. 
Preparation of Standard solution: 
Weigh accurately 10 mg of Bortezomib and transfer into a 
clean, dry 10ml volumetric flask and add 7ml of Methanol 
sonicate to dissolve and removal of air completely and make 
the volume up to the mark with the diluent. Further pipette 
out 0.75ml of the above Bortezomib stock solution into a 
10ml volumetric flask and dilute up to the mark with diluent 
and filtered through 0.45µm membrane filter. 
Preparation of Sample solution: 
Each capsule was weighed and powered by using mortor and 
pestle and 10mg equivalent weight of Bortezomib citrate 
sample was weighed and transferred into 10ml of clean, dry 
volumetric flask. Then add 7ml of diluent and sonicate to 
dissolve for 20min. The volume was made up to 10ml with 
diluent. 
Pipette out 0.75ml of the above solution into a 10ml 
volumetric flask and dilute up to the mark with diluent and 
filtered through 0.45µm membrane filter. 
Procedure: 
Inject the samples by changing the chromatographic 
conditions and record the chromatograms, note the 
conditions of proper peak elution for performing validation 
parameters as per ICH guidelines. 
Mobile Phase Optimization: 
Initially the mobile phase tried was Water, Methanol: Water 
and Acetonitrile: Water with varying proportions. Finally, 
the mobile phase was optimized to Methanol: Water in 
proportion 15:85 v/v respectively. 
Optimization of Column: 
The method was carried out with various C18 columns like 
Phenomenex column, Xterra, and Symmetry C18 column. 
Hypersil C18 (4.6 x 150mm, 5 µ) was found to be ideal as it 
gave good peak shape and resolution at 1.0ml/min flow. The 
sample was injected using 10 ml fixed loop and PDA detector 
was set at a wavelength of 284nm and the run time is 6min. 
RESULTS AND DISCUSSION 
The method developed was validated as per ICH guidelines. 
The system suitability parameters are performed and other 
parameters like Accuracy, Precision, Linearity, Robustness, 
LOD, LOQ are performed by using optimized 
chromatographic conditions. The Retention time of 
Bortezomib was 3.513min. The standard chromatographs 
are shown in Figure 2a. 
System Suitability: 
A standard solution was prepared by using Bortezomib stock 
solution as per test method and was injected for 5 times into 
HPLC column. From the system suitability studies it is 
observed that 
% RSD values were within the specified limit i.e. not more 
than 2. System suitability data was presented in table:1 
Specificity: 
It is the ability to asses unequivocally the analyte in the 
presence of components that may be expected to be present. 
Excipients that are commonly used were spiked into a pre 
weighed quantity of drugs. Appropriate dilutions were 
injected into chromatographic system and the quantities of 
the drugs were determined. Results of the method are 
tabulated in table 2 
Linearity: 
A series of solutions were prepared using Bortezomib 
working standard solution at a concentration levels from 25-
125mg/ml of target concentration and the peak area 
response of all solutions are measured. A graph was plotted 
against the Concentration (mg/ml)on X-axis versus 
area/response on Y-axis. The detector response was found to 
be linear with a correlation coefficient of 0.999. Linearity 
graph is shown in Figure 3 linearity results of the method are 
tabulated in table 3 
Precision: 
Precision studies were performed (Method, Day to day). The 
results are reported in term of Relative standard deviation. 
The repeatability studies were carried out by estimating 
response of 6 different concentrations of Bortezomib and 
reported in terms of % RSD, % RSD was 0.13, for method 
precision it was 0.11 and for day to day precision it was 0.12. 
Precision results of the method are tabulated in table 4 
Accuracy: 
Accuracy of the method was determined by calculating the 
recovery of Bortezomib by the spiked method. Known 
quantity of Bortezomib was added to a pre-determined 
sample solution and the amount of Bortezomib was 
estimated by measuring peak areas. Mean % recovery values 
are within the limit (limit is 98-102%). Accuracy data was 
presented in table 5 & 5a 
LOD and LOQ Limits: 
The level of detection (LOD) and level of Quantification (LOQ) 
were conducted on the basis of standard deviation of the 
response and the slope .The LOD and LOQ for Bortezomib 
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were found to be 5.2 and 15.8 respectively. 
 
Robustness: 
Robustness is a measure of its capacity to remain unaffected 
by small, but deliberated variation in the method parameters 
and gives an indication of its reliability during normal usage. 
Robustness of the method was studied by injecting 0.9 ml 
min-1, 1.0 ml min-1, 1.1ml min-1 and mobile ratio variation 
from more organic phase to less organic phase ratio. The 
method passed robustness test with well % RSD. .Robustness 
data was presented in table 6 
 
Blank: 
 
Figure 2: Chromatogram showing blank (mobile phase preparation)  
 
Figure 2a: Optimized Chromatogram (BortezomibStandard) 
System suitability: 
Table 1: Results of system suitability for Bortezomib 
S.No  
Peak Name 
 
RT 
Area Height 
(µV) 
USP Plate 
Count 
USP Tailing 
1 Bortezo 3.513 2947505 275462 7462 1.1 
2 Bortezom 3.516 2958475 275361 7462 1.1 
3 Bortezom 3.515 2965847 275144 6472 1.1 
4 Bortezom 3.51 2952642 275837 7183 1.1 
5 Bortezom 3.51 2951645 275948 7428 1.1 
Mean   2955223    
Std. Dev.   7114.704    
% RSD   0.24075    
 
Specificity: 
Table 2: Peak results for Assay Standard 
S.No Name RT Area Height USP Tailing USP Plate Count 
1 Bortezomib 3.518 2967593 275837 1.1 6583 
2 Bortezomib 3.517 2967399 275922 1.1 5938 
3 Bortezomib 3.515 2960183 271844 1.1 5883 
 
Table 2a: Peak results for Assay sample 
S.No Name RT Area Height USP Tailing USP Plate Count 
1 Bortezomib 3.511 2983744 275833 1.1 7584 
Laxmi  Prasanna et al                                                                                                  Journal of Drug Delivery & Therapeutics. 2019; 9(1):17-21 
ISSN: 2250-1177                                                                                  [20]                                                                                 CODEN (USA): JDDTAO 
2 Bortezomib 3.511 2958374 275984 1.1 6294 
3 Bortezomib 3.514 2957262 275481 1.1 8194 
%ASSAY = 
      Sample area Weight of standard        Dilution of sample          Purity Weight of Capsule 
  ×  ×   ×     ×                 ×100 
     Standard area Dilution of standard        Weight of sample        100               Label claim 
 
=2966460 / 2965058 × 10/75 × 75/0.0145 × 99.7/100 × 0.0174/12 × 100 
=99.7 
 
The % purity of Bortezomib in pharmaceutical dosage form was found to be 99.7% 
Linearity: 
 
Figure 3: For linearity data 
Table 3: For linearity data 
Conc. Level (%)  Average Peak Area 
33 25 1083048 
66 50 1973321 
100 75 2955166 
133 100 4063921 
166 125 5006038 
 
Precision 
Table 4: Results of repeatability for Bortezomib: 
 
S. No 
 
Peak name 
 
RT 
 
Area(µV*sec) 
 
Height(µV) 
 
USP Plate Count 
USP Tailing 
1 Bortezomib 3.528 2958333 275983 7583 1.1 
2 Bortezomib 3.516 2951049 275911 7593 1.1 
3 Bortezomib 3.514 2959294 275955 8674 1.1 
4 Bortezomib 3.519 2953391 275921 7958 1.1 
5 Bortezomib 3.512 2950744 275221 9745 1.1 
Mean   2954562    
Std.dev   4028.083    
%RSD   0.136334    
 
Table 4a: Results of Intermediate precision day1 for Bortezomib 
S.No  
Peak Name 
 
RT 
Area 
(µV*sec) 
Height 
(µV) 
 
USP Plate count 
 
USPTailing 
1 Bortezom 3.517 2957344 275838 7194 1.1 
2 Bortezom 3.514 2951847 275629 8573 1.1 
3 Bortezom 3.517 2950834 276931 7655 1.1 
4 Bortezom 3.517 2957155 275623 7944 1.1 
5 Bortezom 3.512 2950185 275184 7562 1.1 
6 Bortezom 3.518 2951750 275193 7585 1.1 
Mean   2953186    
Std. Dev.   3207.331    
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% RSD   0.108606    
 
Table 4b: Results of Intermediate precision Day 2 for Bortezomib 
S.No  
Peak Name 
 
RT 
Area (µV*sec) Height (µV)  
USP Plate count 
 
USPTailing 
1 Bortezomib 3.513 2951848 275929 7937 1.1 
2 Bortezomib 3.511 2958275 275222 7284 1.1 
3 Bortezomib 3.516 2950185 275857 7684 1.1 
4 Bortezomib 3.518 2957462 27516 7917 1.1 
5 Bortezomib 3.511 2957541 27516 7585 1.1 
6 Bortezomib 3.519 2951164 27515 7192 1.1 
Mean   2954413    
Std. Dev.   3715.025    
% RSD   0.125745    
 
Table 5: Results of Accuracy for concentration-50%, 100% and 150% 
S.No Conc. RT Area Height USP Tailing USP Plate Count 
1 50% 3.519 1493763 275837 1.1 6453 
2 50% 3.520 1493923 275819 1.1 7584 
3 50% 3.519 1492575 275083 1.1 6785 
4 100% 3.516 2983722 275829 1.1 7483 
5 !00% 3.518 2984722 275143 1.1 6935 
6 100% 3.519 2967382 275063 1.1 6285 
7 150% 3.517 4462011 275622 1.1 7483 
8 150% 3.519 4469483 275922 1.1 7265 
9 150% 3.520 4489583 276331 1.1 7194 
 
Table 5a: Accuracy results for Bortezomib 
%Concentration (at 
specification Level) 
Area Amount 
Added(ppm) 
Amount Found(ppm) %Recovery Mean 
Recovery 
50% 1483420 37.5 36.96 98.5%  
98.8 
% 
100% 2978609 75 74.1 98.8% 
150% 4473692 112.5 111.56 99.1% 
 
Robustness: 
Table 6: Results for Robustness 
Parameter used for sample analysis Peak Area RT Theoretical plates Tailing factor 
Actual Flow rate of 1.0 mL/min 2955764 3.513 7483 1.1 
Less Flow rate of 0.9 mL/min 2958393 3.897 6028 1.1 
More Flow rate of 1.1 mL/min 2956411 3.218 6928 1.2 
Less organic phase 2950683 3.707 6733 1.2 
More organic phase 2957265 3.350 6285 1.1 
 
CONCLUSION 
In this study a simple, rapid,and reliable RP-HPLC method 
was developed and validated for the determination of 
Bortezomib in capsule dosage form. From the results 
obtained, we conclude that the suggested method showed 
high sensitivity, accuracy, and specificity. Moreover, this 
method was simple and economical and can be employed for 
the routine quality control of Bortezomib in pharmaceutical 
dosage forms. 
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